Your browser doesn't support javascript.
loading
[A Case of Pappilary Renal Cell Caircinoma which Responded Well to the Combination Therapy of Ipilimumab and Nivolumab --A CASE REPORT-].
Fukatani, Yusuke; Daizumoto, Kei; Kadoriku, Fumiya; Yamamoto, Hiraku; Sasaki, Yutaro; Ozaki, Keisuke; Ueno, Yoshiteru; Tuda, Megumi; Kusuhara, Yoshito; Fukawa, Tomoya; Yamamoto, Yasuyo; Yamaguchi, Kunihisa; Takahashi, Masayuki; Kanayama, Hiroomi; Niki, Mariko; Uehara, Hisanori.
Afiliação
  • Fukatani Y; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Daizumoto K; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Kadoriku F; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Yamamoto H; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Sasaki Y; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Ozaki K; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Ueno Y; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Tuda M; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Kusuhara Y; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Fukawa T; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Yamamoto Y; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Yamaguchi K; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Takahashi M; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Kanayama H; The Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Niki M; The Department of Dermatology, Institute of Biomedical Sciences, Tokushima University Graduate School.
  • Uehara H; The Department of Pathology, Tokushima University Hospital.
Hinyokika Kiyo ; 68(4): 107-111, 2022 Apr.
Article em Ja | MEDLINE | ID: mdl-35613898
We report a case of papillary renal cell carcinoma that responded well to the combination of ipilimumab and nivolumab. The patient was a 68-year-old male who was being followed up for a small left renal mass without treatment. Two years later, computed tomography (CT) showed enlarged cervical and para-aortic lymph nodes, and lymph node biopsy suggested metastases of the cancer. After resection of the renal tumor, we performed pararenal aortic lymph node biopsy, and we diagnosed the case as papillary renal cell carcinoma type 1 with lymph node metastasis. The combination of ipilimumab and nivolumab each metastatic site showed regression on CT. Since immune-related adverse events occurred during the therapy nivolumab was discontinued, but partial response of the metastases was maintained.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Idioma: Ja Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Idioma: Ja Ano de publicação: 2022 Tipo de documento: Article